Vaccine Plus Immunotherapy for Better Cancer Outcomes
PD1-Based TWIST1 Cancer Vaccine
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology combines checkpoint immunotherapy with PD1-based vaccination to elicit long-term TWIST1-specific T cell responses, enhancing cancer treatment efficacy. It has shown promising results in treating mesothelioma and breast cancer by inducing durable immunity and achieving remission in 60% of mesothelioma cases. The global cancer vaccines market, valued at $4.2 billion in 2019, is expected to grow, highlighting the potential impact of this innovation. This approach represents a significant advancement in cancer vaccines, offering new hope for patients with tumors resistant to current therapies.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Vaccines; Biotechnology
